Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies
NCT02182245 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22
Last updated 2025-01-23
Summary
The primary objectives of this trial were to determine the safety, tolerability, and MTD of BIBF 1120 when added to standard therapy with carboplatin and paclitaxel
Conditions
- Genital Neoplasms, Female
Interventions
- DRUG
-
BIBF 1120
- DRUG
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-10-01
- Primary Completion
- 2007-01-01
More Related Trials
-
LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors
NCT01159418 ·Status: UNKNOWN ·Phase: PHASE1
-
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
NCT01938846 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer
NCT02254031 ·Status: TERMINATED ·Phase: PHASE1
-
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
NCT06756932 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
NCT01219699 ·Status: COMPLETED ·Phase: PHASE1
-
Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates
NCT01484080 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
NCT02051751 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer
NCT02599363 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
NCT01623349 ·Status: COMPLETED ·Phase: PHASE1
-
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer
NCT03081234 ·Status: WITHDRAWN ·Phase: PHASE3
-
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
NCT05226871 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
NCT01209195 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
NCT04958239 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer
NCT00717340 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
NCT03893955 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Phase IIa Study of BRY812 Monotherapy in Advanced Gynecological Malignancies
NCT07311538 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
NCT01915576 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
NCT07306559 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer
NCT02058381 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer
NCT01023204 ·Status: COMPLETED ·Phase: PHASE2
-
A Confirmation Study of Eribulin in Combination With Capecitabine
NCT01323530 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
NCT05905341 ·Status: WITHDRAWN ·Phase: PHASE1
-
Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer
NCT02569489 ·Status: WITHDRAWN ·Phase: PHASE1
-
Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast
NCT02204046 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients
NCT01795586 ·Status: COMPLETED ·Phase: PHASE1